e-learning
resources
ERJ
2008
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia
Ramirez P. , Garcia M. A. , Ferrer M. , Aznar J. , Valencia M. , Sahuquillo J. M. , Menendez R. , Asenjo M. A. , Torres A.
Source:
Eur Respir J 2008; 31: 356-362
Journal Issue:
February
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ramirez P. , Garcia M. A. , Ferrer M. , Aznar J. , Valencia M. , Sahuquillo J. M. , Menendez R. , Asenjo M. A. , Torres A.. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008; 31: 356-362
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Predictive value of procalcitonin in ventilator-associated pneumonia
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
Usefulness of C-reactive protein and procalcitonin levels in pulmonary tuberculosis
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008
Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study
Source: Eur Respir J 2009; 34: 1364-1375
Year: 2009
Prognostic value of procalcitonin in community-acquired pneumonia
Source: Eur Respir J 2011; 37: 384
Year: 2011
Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia
Source: Eur Respir J 2010; 35: 805-811
Year: 2010
Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)?
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Serum procalcitonin and community-acquired pneumonia in childhood
Source: Eur Respir J 2005; 26: Suppl. 49, 167s
Year: 2005
C-reactive protein in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006
Comparision of procalcitonin and CURB-65 in pneumonia
Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Year: 2012
Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
The role of procalcitonin in predicting severity and clinical course of aspiration pneumonia
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Diagnostic accuracy of inflammatory biomarkers in bronchoalveolar lavage from patients with ventilator-associated pneumonia
Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept